SB
TRIL

Samsara BioCapital’s Trillium Therapeutics Inc. TRIL Stock Holding History

Samsara BioCapital’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-71,619
Closed -$24K – 22
2019
Q2 		$24K Hold
71,619
– – 0.02% 21
2019
Q1 		$47K Hold
71,619
– – 0.04% 18
2018
Q4 		$122K Buy
+71,619
New +$215K 0.12% 16

Other funds holding TRIL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Samsara BioCapital's TRIL Position: Q3 2019 in Review

Samsara BioCapital sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2019, closing a stake of 71,619 shares — an estimated $24K sold.

Samsara BioCapital first reported a position in TRIL in Q4 2018 and held it in 3 quarters. The position peaked at $122K in Q4 2018. 19 funds tracked by Wall St. Rank hold TRIL as of Q3 2019.

  • Samsara BioCapital reported no remaining Trillium Therapeutics Inc. position as of Q3 2019 after selling out during the quarter.
  • Samsara BioCapital sold 71,619 Trillium Therapeutics Inc. shares in Q3 2019, an estimated $24K.
  • Samsara BioCapital first reported a position in Trillium Therapeutics Inc. in Q4 2018 and held it in 3 quarters.
  • Samsara BioCapital's Trillium Therapeutics Inc. position peaked at $122K in Q4 2018.
  • 19 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2019.

Based on Samsara BioCapital's 13F filing for Q3 2019, filed 14 Nov 2019.